Johnson and Johnson 2014 Annual Report Download - page 4

Download and view the complete annual report

Please find page 4 of the 2014 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

health care in all corners of the world. For us,
this involves preventing the spread of deadly
infectious diseases, solving the twin challenges
of over-nutrition and under-nutrition, leading
breakthrough medical research and empowering
citizens to take responsibility for managing their
own health and wellness.
There is no company better positioned
to help meet these urgent needs than
Johnson & Johnson.
Given the progress we’ve made in our business
over the past several years, we’re evolving our
approach, placing an even greater emphasis on
innovation and accelerating growth. Continued
commitment to excellence in execution is a non-
negotiable part of the process.
To succeed, we have clear goals and priorities:
We will grow our R&D pipeline. Over the
coming years our pharmaceutical pipeline is
poised to yield a consistent flow of new product
filings that will allow us to bring new medicines
and technologies to patients. We will continue
to build our pipeline in order to stay in the
forefront.
We will lead in consumer health care markets.
We will aim to expand our leadership in targeted
markets by holistically addressing critical-need
states in over-the-counter medicines, as well as
oral care, baby and skin care markets.
We will strengthen our position in medical
devices. Our focus will be on accelerating growth
with innovative products and by transforming
our go-to-market models to better serve our
customers and patients.
The world today requires the very best that
Johnson & Johnson has to offer, and we are
constantly striving to come up with ways we can
innovate and lead. We have made very deliberate
choices about our portfolio and have focused our
energies on capturing the greatest opportunities
we have to advance patient care.
We are confident in the future of
Johnson & Johnson for four reasons:
• Our core businesses are strong and
positioned to continue expanding their
leadership;
• We have an exciting and deep product
pipeline across the entire enterprise;
• We are changing the way we interact
with our customers; and,
• We are evolving our structure to be more
effective and efficient to drive growth.
In this interconnected global society in which
we live and do business, I have come to realize
through my travels around the world with
Johnson & Johnson that all health care is local
and personal. With approximately 126,500
people working at our 265 operating companies
in 60 countries across a broad range of medical
specialties and community health needs, we
have unique insights and capabilities that can
help address the most formidable challenges.
I am very proud of our colleagues around the
globe who are focused on doing all they can
every single day to care for the world, one
person at a time.
As the largest and most diversified health
care company in the world, we have both the
opportunity and responsibility to help meet these
challenges with boldness, vision and a driving
APPROXIMATELY
126,500 PEOPLE
WORKING
AT OUR 265
OPERATING
COMPANIES IN
60 COUNTRIES
II • CHAIRMAN’S LETTER